LivaNova (NASDAQ:LIVN) Receives New Coverage from Analysts at The Goldman Sachs Group

Research analysts at The Goldman Sachs Group initiated coverage on shares of LivaNova (NASDAQ:LIVN) in a research note issued on Friday, Marketbeat reports. The firm set a “buy” rating and a $65.00 price target on the stock. The Goldman Sachs Group’s price objective would indicate a potential upside of 20.75% from the stock’s previous close.

LIVN has been the subject of several other research reports. Stifel Nicolaus raised their target price on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Needham & Company LLC raised their price objective on LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Robert W. Baird upgraded LivaNova from a “neutral” rating to an “outperform” rating and upped their target price for the company from $55.00 to $66.00 in a report on Tuesday, September 17th. Finally, Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, LivaNova has a consensus rating of “Buy” and a consensus target price of $69.83.

LivaNova Price Performance

LIVN stock opened at $53.83 on Friday. LivaNova has a one year low of $42.75 and a one year high of $64.47. The firm has a 50-day moving average of $48.63 and a two-hundred day moving average of $53.41. The firm has a market capitalization of $2.92 billion, a PE ratio of -89.72 and a beta of 1.00. The company has a current ratio of 3.45, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.15. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The business had revenue of $318.60 million for the quarter, compared to analyst estimates of $305.05 million. On average, analysts forecast that LivaNova will post 2.58 earnings per share for the current year.

Institutional Investors Weigh In On LivaNova

Institutional investors have recently made changes to their positions in the company. Hexagon Capital Partners LLC raised its position in LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after acquiring an additional 370 shares in the last quarter. Fifth Third Bancorp increased its stake in shares of LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of LivaNova during the 1st quarter valued at $84,000. Canada Pension Plan Investment Board acquired a new stake in shares of LivaNova in the 2nd quarter valued at $88,000. Finally, Acadian Asset Management LLC bought a new stake in LivaNova in the first quarter worth $94,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.